Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2899055 | 0.85 | NPC1 (0.41) | NPC1RAB9APOLBTAS1R3TAS1R1 | |
| SCHEMBL2901313 | 0.83 | POLB (0.37) | NPC1RAB9APOLBTAS1R3TAS1R1 | |
| SCHEMBL4666210 | 0.78 | POLB (0.45) | NPC1RAB9APOLBHPGDALDH1A1 | |
| SCHEMBL2900855 | 0.76 | POLB (0.36) | NPC1RAB9APOLBHPGDALDH1A1 | |
| SCHEMBL14697697 | 0.76 | POLB (0.42) | NPC1RAB9APOLBHPGDALDH1A1 | |
| SCHEMBL2783255 | 0.75 | CHRM1 (0.43) | POLB | |
| SCHEMBL2786923 | 0.74 | POLB (0.41) | NPC1RAB9APOLBHPGDALDH1A1 | |
| SCHEMBL2695475 | 0.74 | NPC1 (0.48) | NPC1RAB9APOLBP2RX7 | |
| SCHEMBL4639194 | 0.72 | POLB (0.59) | RAB9APOLBHPGDALDH1A1KDM4E | |
| SCHEMBL27779125 | 0.71 | ALDH1A1 (0.48) | NPC1RAB9APOLBTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213167-B1 | Anthranilamide derivatives and their use for the control of insects and acari | SYNGENTA PARTICIPATIONS AG (CH) | 2013-07-31 | — | — | EP | disclosed |
| US-8278464-B2 | Insecticides | SYNGENTA CROP PROTECTION LLC (US) | 2012-10-02 | — | — | US | disclosed |
| US-8084474-B2 | Insecticides | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2213167-A1 | Anthranilamide derivatives and their use for the control of insects and acari | Syngenta Participations AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100168066-A1 | NOVEL INSECTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| EP-1976385-A2 | ANTHRANILAMIDE DERIVATIVES AND THEIR USE FOR THE CONTROL OF INSECTS AND ACARI | Syngeta Participations AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007080131-A2 | ANTHRANILAMIDE DERIVATIVES AND THEIR USE FOR THE CONTROL OF INSECTS AND ACARI | SYNGENTA PARTICIPATIONS AG (CH) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168066-A1 | NOVEL INSECTICIDES | DDT, ACHE, CYP4F11 | NPC1 1329/4885RAB9A 738/4885POLB 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.